SEC Comment Letter for Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — May 13, 2020
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: May 13, 2020 · CIK: 0001534120 · Accession: 0000000000-20-004251
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238197
Letter
United States securities and exchange commission logo May 13, 2020 Christopher Sullivan Interim Chief Financial Officer Cerecor Inc. 540 Gaither Road, Suite 400 Rockville, Maryland 20850 Re:Cerecor Inc. Registration Statement on Form S-3 Filed May 12, 2020 File No. 333-238197 Dear Mr. Sullivan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Donald R. Reynolds, Esq.
Show Raw Text
United States securities and exchange commission logo
May 13, 2020
Christopher Sullivan
Interim Chief Financial Officer
Cerecor Inc.
540 Gaither Road, Suite 400
Rockville, Maryland 20850
Re:Cerecor Inc.
Registration Statement on Form S-3
Filed May 12, 2020
File No. 333-238197
Dear Mr. Sullivan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Donald R. Reynolds, Esq.